Protalix gets marketing approval in Australia for ELELYSO to treat Gaucher disease

Israel-based biopharmaceutical firm Protalix BioTherapeutics has received approval from the Australian Therapeutic Goods Administration (TGA) for ELELYSO (taliglucerase alfa) for injection, as a long-term enzyme replacement therapy for treatment of G…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news